These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36015253)

  • 1. Factors Affecting the Metabolic Conversion of Ciprofloxacin and Exposure to Its Main Active Metabolites in Critically Ill Patients: Population Pharmacokinetic Analysis of Desethylene Ciprofloxacin.
    Šíma M; Bobek D; Cihlářová P; Ryšánek P; Roušarová J; Beroušek J; Kuchař M; Vymazal T; Slanař O
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.
    Spooner AM; Deegan C; D'Arcy DM; Gowing CM; Donnelly MB; Corrigan OI
    BMC Clin Pharmacol; 2011 Aug; 11():11. PubMed ID: 21816053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin.
    Frost RW; Lettieri JT; Krol G; Shamblen EC; Lasseter KC
    Clin Pharmacol Ther; 1989 Jun; 45(6):608-16. PubMed ID: 2731404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciprofloxacin pharmacokinetics in burn patients.
    Garrelts JC; Jost G; Kowalsky SF; Krol GJ; Lettieri JT
    Antimicrob Agents Chemother; 1996 May; 40(5):1153-6. PubMed ID: 8723457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function.
    Bergan T; Thorsteinsson SB; Rohwedder R; Scholl H
    Chemotherapy; 1989; 35(6):393-405. PubMed ID: 2612228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.
    Forrest A; Ballow CH; Nix DE; Birmingham MC; Schentag JJ
    Antimicrob Agents Chemother; 1993 May; 37(5):1065-72. PubMed ID: 8517693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Corley A; Diehl A; Levkovich BJ; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Roberts JA; Shekar K; Fraser JF;
    Anaesth Crit Care Pain Med; 2022 Jun; 41(3):101080. PubMed ID: 35472580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofloxacin in critically ill subjects: considering hepatic function, age and sex to choose the optimal dose.
    Li X; Zoller M; Fuhr U; Huseyn-Zada M; Maier B; Vogeser M; Zander J; Taubert M
    J Antimicrob Chemother; 2019 Mar; 74(3):682-690. PubMed ID: 30500905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excretion pattern of enrofloxacin after oral treatment of chicken broilers.
    Slana M; Pahor V; Cvitkovič Maričič L; Sollner-Dolenc M
    J Vet Pharmacol Ther; 2014 Dec; 37(6):611-4. PubMed ID: 24731224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections.
    Cios A; Wyska E; Szymura-Oleksiak J; Grodzicki T
    Exp Gerontol; 2014 Sep; 57():107-13. PubMed ID: 24862289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule).
    Staib AH; Beermann D; Harder S; Fuhr U; Liermann D
    Am J Med; 1989 Nov; 87(5A):66S-69S. PubMed ID: 2589389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
    Roger C; Wallis SC; Louart B; Lefrant JY; Lipman J; Muller L; Roberts JA
    J Antimicrob Chemother; 2016 Jun; 71(6):1643-50. PubMed ID: 26957490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved high-performance liquid chromatographic determination of ciprofloxacin and its metabolites in human specimens.
    Mack G
    J Chromatogr; 1992 Nov; 582(1-2):263-7. PubMed ID: 1491053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg.
    Szałek E; Tomczak H; Kamińska A; Grabowski T; Smuszkiewicz P; Matysiak K; Wolc A; Kaczmarek Z; Grześkowiak E
    Adv Med Sci; 2012; 57(2):217-23. PubMed ID: 22968336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients.
    Aoyama T; Hirata K; Hirata R; Yamazaki H; Yamamoto Y; Hayashi H; Matsumoto Y
    J Clin Pharm Ther; 2012 Jun; 37(3):356-63. PubMed ID: 21883330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches.
    Conil JM; Georges B; de Lussy A; Khachman D; Seguin T; Ruiz S; Cougot P; Fourcade O; Houin G; Saivin S
    Int J Antimicrob Agents; 2008 Dec; 32(6):505-10. PubMed ID: 18768301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.
    Kashuba AD; Ballow CH; Forrest A
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1860-5. PubMed ID: 8843294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
    Udy AA; Lipman J; Jarrett P; Klein K; Wallis SC; Patel K; Kirkpatrick CM; Kruger PS; Paterson DL; Roberts MS; Roberts JA
    Crit Care; 2015 Jan; 19(1):28. PubMed ID: 25632974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.